Propafenone Hydrochloride Extended-Release Capsules Recalled for CGMP Deviations
Glenmark Pharmaceuticals Inc., USA is recalling Propafenone Hydrochloride Extended-Release Capsules 225mg due to Current Good Manufacturing Practice (CGMP) deviations. The recall affects lot #17230819 with expiration date March 2025, distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is a Class II recall driven by CGMP manufacturing deviations. The source text does not report any illnesses or injuries, and CGMP deviations typically indicate potential quality issues rather than documented harm. This meets the criteria for a Moderate severity rating—manufacturing/labeling concerns without reported adverse health consequences.
Plain-English summary
Glenmark Pharmaceuticals Inc., USA is voluntarily recalling Propafenone Hydrochloride Extended-Release Capsules 225mg in 60-count bottles (NDC# 68462-408-60) due to Current Good Manufacturing Practice (CGMP) deviations. The affected lot is #17230819 with an expiration date of March 2025. The product was manufactured by Glenmark Pharmaceuticals Limited in Pithampur, Madhya Pradesh, India, and distributed nationwide across the United States.
Propafenone hydrochloride is a prescription antiarrhythmic medication used to treat abnormal heart rhythms. CGMP deviations may affect product quality and consistency. Patients currently taking this medication should contact their healthcare provider or pharmacist to discuss whether they have a bottle from the affected lot and what steps to take.
Consumers who have this medication should check the lot number and expiration date on their bottle. If they have lot #17230819 (exp. Mar-25), they should contact their pharmacy or healthcare provider before taking any further doses. The company initiated this recall on March 13, 2025.
The recalled product
- Product
- PROPAFENONE HYDROCHLORIDE (PROPAFENONE HYDROCHLORIDE)
- Brand
- PROPAFENONE HYDROCHLORIDE
- Manufacturer
- Glenmark Pharmaceuticals Inc., USA
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # 17230819
- exp. date Mar-25
UPCs (3)
- 0368462409602
- 0368462410608
- 0368462408605
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 39 recalled by Glenmark Pharmaceuticals Inc., USA under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 39 products in this recall →Related recalls
Same brand · PROPAFENONE HYDROCHLORIDE
- ModeratePropafenone Hydrochloride Extended-Release Capsules Recalled for CGMP Deviations
FDA (Drugs) · 2025-04-16
- ModeratePropafenone Hydrochloride Extended-Release Capsules Recalled for CGMP Deviations
FDA (Drugs) · 2025-04-16
- ModeratePropafenone Hydrochloride Extended-Release Capsules Recalled for CGMP Deviations
FDA (Drugs) · 2025-04-16
Same manufacturer · Glenmark Pharmaceuticals Inc., USA
See all →- ModerateAzelaic Acid Gel 15% Recalled Over Grainy, Gritty, or Sandy Texture
FDA (Drugs) · 2026-08-05
- ModerateAlyacen 7/7/7 birth control tablets failed total impurities specification
FDA (Drugs) · 2026-06-24
- ModerateOndansetron tablets recalled because blister packs are not fully sealed
FDA (Drugs) · 2026-01-07
- CriticalFrozen chopped methi recalled after testing positive for Salmonella
FDA (Drugs) · 2025-12-17
- ModerateBisoprolol and hydrochlorothiazide tablets recalled over traces of another drug
FDA (Drugs) · 2025-12-10
Same hazard · cgmp deviation
See all →- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModerateBaxter Recalls Clindamycin Phosphate Injection Due to CGMP Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09